Overall rank by patents
#26,220
Across all tracked assignees
USPTO PatentsView assignee record - 10 granted patents across 11 technology areas, active 2016–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: Y02E (REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION).
The verdict
EXRO holds 10 US patents across 11 technology areas, rank #26,220 of 50,000 tracked assignees.
EXRO Technologies Inc. has been granted 10 US utility patents between 2016 and 2024, placing EXRO Technologies Inc. at rank #26,220 across all assignees tracked by PlainPatent. This portfolio spans 11 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.8 claims per patent with primary concentration in Y02E (REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION). As a Foreign Corporation, EXRO Technologies Inc. is one of the more focused assignees in the PatentsView dataset. By volume, EXRO sits between Evotec International Gmbh (10 patents, rank #26,216) and Eyeway Vision Ltd. (10 patents, rank #26,224) - the closest US assignees by grant volume. The composite Innovation Score of 50.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 5 grants, compared with 5 in the 2015–2019 window, a +0% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. EXRO Technologies Inc.'s 16.8 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 11 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark EXRO Technologies Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
EVOTEC INTERNATIONAL GmbH
10 patents
EXACTO, INC.
10 patents
EXIMIS SURGICAL INC.
10 patents
EXOSTEM BIOTEC LTD.
10 patents
EXTEN Technologies, Inc.
10 patents
EYE LABS, LLC
10 patents
EYECAM, INC.
10 patents
EYEWAY VISION LTD.
10 patents
EXRO TECHNOLOGIES INC.
10 patents
What this shows EXRO holds 10 patents at rank #26,220, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
EXRO's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
50 Top 14% higher than 86% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 1 | 10.0% |
| 2017 | 4 | 40.0% |
| 2023 | 2 | 20.0% |
| 2024 | 3 | 30.0% |
Top 11 of 11 technology areas
Overall rank by patents
#26,220
Across all tracked assignees
50.1 out of 100
How to use this portfolio
EXRO's 10 grants land it in the top 14% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.